We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Evaluated for Detection of Helicobacter pylori

By LabMedica International staff writers
Posted on 02 Aug 2011
Print article
The efficacy of a new polyclonal enzyme immunoassay (EIA) for the detection of Helicobacter pylori antigen in feces has been determined.

The immunoassay has been compared with histology, rapid urease test, carbon-13 (13C)-urea breath test, and serology to determine the optimal cut-off value for screening a population at risk.

Scientists at Seoul National University (Seoul, Korea) prospectively enrolled 515 patients undergoing a routine health check-up. H. pylori infection was defined if at least two of four of the following tests: histology, rapid urease test, 13C-urea breath test, and serology, were positive. Stool samples were analyzed using a new polyclonal EIA stool antigen test, the EZ-STEP H. pylori, which was performed by the capture of polyclonal antibodies to H. pylori absorbed in microwells. The optimal cut-off value was determined by the receiver–operator characteristic curve. The diagnostic performance of each test was evaluated with regard to the histological diagnosis of atrophic gastritis (AG)/intestinal metaplasia (IM), degree of AG/IM, and old age.

The EZ-STEP H. pylori stool antigen test (Dinona Inc., Seoul, Korea) had a sensitivity of 93.1%, and specificity of 94.6% and was accurate 93.8% of the time. The sensitivity of histology, rapid urease test, and the 13C-urea breath test ranged from 89.1% to 97.6%, and their specificity was greater than 98%. The serological test, an enzyme-linked immunosorbent assay, identified as the H. pylori IgG EIA Well (Radim diagnostics, Rome, Italy) had high sensitivity, but low specificity. The stool antigen test still showed good diagnostic performance in the setting of progression of AG/IM and in patients over 40 years.

The authors concluded that the diagnostic performance of the new polyclonal stool antigen EIA was comparable to that of other methods used in the diagnosis of H. pylori infection in the screening population if an optimal cut-off value was determined. The stool antigen test might still be effective for the detection of H. pylori in the clinical settings of AG and/or IM and elderly patients. The study was published in June 2011, in the Journal of Gastroenterology and Hepatology.

Related Links:
Seoul National University
Radim diagnostics


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.